The panel also called on Douglas Throckmorton, MD,, deputy director at the Food and Drug Administration’s Center for Drug Evaluation and Research, for answers regarding delays in the approval of a competing epinephrine auto-injector.
“There is justified outrage from families and schools across the country struggling to afford the high cost of EpiPens,” committee Chairman and Rep. Jason Chaffetz (R-Utah) and Rep. Elijah Cummings (D-Md.) said in a statement.
The Senate Permanent Select Subcommittee on Investigations has also opened a preliminary inquiry on Canonsburg, Pa.-based Mylan.
More articles on supply chain:
Market exclusivity main factor in high drug prices, study finds
Supply chain salaries to increase nearly 3% in 2017
5 myths about the EpiPen controversy